Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study.

Andrea Wang-Gillam Kian-Huat Lim Robert R McWilliams Rama Suresh Albert C Lockhart Amberly Brown Marcus A Breden Jad I Belle John M Herndon Savannah J Bogner Katrina S Pedersen Benjamin Tan Nicholas Boice Abhi Acharya Mina Abdiannia Feng Gao Harry H Yoon Mojun Zhu Nikolaos A Trikalinos Lee Ratner Olivia Aranha William G Hawkins Brett H Herzog David G DeNardo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.

Keyphrases

locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
rectal cancer
current status
radiation therapy
open label
clinical trial
case control
combination therapy
tyrosine kinase
epidermal growth factor receptor
study protocol
double blind